Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
22nd January 2021 | Rita Jain | 20,000 | Grant/award etc. | $0.00 | |
21st December 2020 | Steven C Gilman | 4,000 | Open or private purchase | $6.25 | $25,000.00 |
23rd October 2020 | Scott A Canute | 13,516 | Sale back to the issuer | $0.00 | |
1st October 2020 | Steven C Gilman | 7,796 | Sale back to the issuer | $0.00 | |
11th August 2020 | Michael Thomas Heffernan | 13,071 | Open or private sale | $19.13 | $250,048.23 |
5th August 2020 | Steven C Gilman | 13,000 | Exercise of derivative | $10.63 | $138,190.00 |
5th August 2020 | Steven C Gilman | 13,000 | Open or private sale | $32.75 | $425,750.00 |
29th July 2020 | Steven C Gilman | 10,000 | Open or private sale | $29.70 | $297,000.00 |
29th July 2020 | Steven C Gilman | 10,000 | Exercise of derivative | $10.63 | $106,300.00 |
22nd July 2020 | Steven C Gilman | 10,000 | Grant/award etc. | $10.63 | $106,300.00 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Akebia Therapeutics, Inc. is a biopharmaceutical company. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat.
29th November 2020
15th November 2020
6th November 2020
6th November 2020